Awards as PI
| Funding | ||
|---|---|---|
| Strategic Partnership I | A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells [REDACTED] | $9,363,335 |
Total: $9,363,335.00 |
